MENU
WGO
Back to Top
World Gastroenterology Organisation
World Gastroenterology Organisation
Follow
WGO: Facebook WGO: Twitter
Share

Inflammatory Bowel Disease (IBD)

Level: Meta-analyses, Systematic reviews, Practice guidelines: 98 Abstracts

Legend: : Key Development,  : Very Important,  : Important, [no star]: Special Mention

   

Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis.
Ungaro R, Bernstein CN, Gearry R, Hviid A, Kolho KL, Kronman MP, Shaw S, Van Kruiningen H, Colombel JF, Atreja A., Am J Gastroenterol. 2014 Nov;109(11):1728-38. doi: 10.1038/ajg.2014.246. Epub 2014 Sep 16. Review.
Comments: Exposure to AB increases risk of new-onset CD

   

Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis.
Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus EV Jr., Gastroenterology. 2015 Jan;148(1):64-76.e2; quiz e14. doi: 10.1053/j.gastro.2014.09.031. Epub 2014 Sep 26. Review.
Comments: Anti-TNF prevents post-surgical recurrence

 

Combination therapy with infliximab and azathioprine is superior to monotherapywith either agent in ulcerative colitis.
Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, vanHoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P., Gastroenterology. 2014 Feb;146(2):392-400.e3.

Comments: Anti-tumor necrosis factor-a-naive patients with moderate to severe UC treated with infliximab plus azathioprine were more likely to achieve corticosteroid-free remission at 16 weeks than those receiving either monotherapy.

 

Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
Ordás I, Rimola J, Rodríguez S, Paredes JM, Martínez-Pérez MJ, Blanc E, Arévalo JA, Aduna M, Andreu M, Radosevic A,Ramírez-Morros AM, Pinó S, Gallego M, Jauregui-Amezaga A, Ricart E, Panés J., Gastroenterology. 2014 Feb;146(2):374-82.e1. doi: 10.1053/j.gastro.2013.10.055.Epub 2013 Oct 29.

Comments: MRE evaluates ulcer healing with a high level of accuracy when ileocolonoscopy is used as the reference standard.

 

Subcutaneous golimumab maintains clinical response in patients withmoderate-to-severe ulcerative colitis.
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR,Collins J, Järnerot G, Rutgeerts P; PURSUIT-Maintenance Study Group., Gastroenterology. 2014 Jan;146(1):96-109.e1. doi: 10.1053/j.gastro.2013.06.010.Epub 2013 Jun 14.

Comments: SC golimumab, a fully human monoclonal antibody to tumor necrosis factor-a (TNFa), at 50 mg or 100 mg maintained clinical response through week 54 in pts with moderate-to-severe active UC who responded to induction therapy with golimumab.

 

Subcutaneous golimumab induces clinical response and remission in patients withmoderate-to-severe ulcerative colitis.
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR,Collins J, Järnerot G, Hibi T, Rutgeerts P; PURSUIT-SC Study Group., Gastroenterology. 2014 Jan;146(1):85-95; quiz e14-5. doi:10.1053/j.gastro.2013.05.048. Epub 2013 Jun 2.

Comments: SC golimumab, a fully human monoclonal antibody to tumor necrosis factor-a (TNFa) induces clinical response, remission, and mucosal healing in active UC.

 

Clinical disease activity, C-reactive protein normalisation and mucosal healingin Crohn's disease in the SONIC trial.
Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ., Gut. 2014 Jan;63(1):88-95. doi: 10.1136/gutjnl-2013-304984. Epub 2013 Aug 23.

Comments: Half the patients under azathioprine and/or infliximab in clinical remission have endoscopic and/or CRP evidence of residual active CD. Clinical symptoms as scored by CDAI are not a reliable measure of the underlying inflammation.

 

New therapeutic avenues in ulcerative colitis: thinking out of the box.
Torres J, Danese S, Colombel JF., Gut. 2013 Nov;62(11):1642-52. doi: 10.1136/gutjnl-2012-303959.

Comments: Important overview on new modalities in UC.

 

Recent advances: Personalised use of current Crohn's disease therapeutic options.
Vermeire S, Ferrante M, Rutgeerts P., Gut. 2013 Oct;62(10):1511-5. doi: 10.1136/gutjnl-2012-303958.

Comments: Important review on propects in CD.

 

Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.
Panés J, López-Sanromán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y, Domènech E, Piqueras M, Gomez-García M, Gutiérrez A, Taxonera C, Sans M; AZTEC Study Group., Gastroenterology. 2013 Oct;145(4):766-74.e1. doi: 10.1053/j.gastro.2013.06.009.Epub 2013 Jun 13.

Comments: Prospective double-blind trial of adults with recent (<8 wks) CD given azathioprine (2.5 mg/kg) or placebo in addition to corticosteroids. Early azathioprine was no more effective than placebo to achieve sustained corticosteroid-free remission but was more effective in preventing moderate to severe relapse in a post hoc analysis.

 

Genetic factors conferring an increased susceptibility to develop Crohn's diseasealso influence disease phenotype: results from the IBDchip European Project.
Cleynen I, González JR, Figueroa C, Franke A, McGovern D, Bortlík M, CrusiusBJ, Vecchi M, Artieda M, Szczypiorska M, Bethge J, Arteta D, Ayala E, Danese S,van Hogezand RA, Panés J, Peña SA, Lukas M, Jewell DP, Schreiber S, Vermeire S,Sans M., Gut. 2013 Nov;62(11):1556-65. doi: 10.1136/gutjnl-2011-300777. Epub 2012 Dec 21.

Comments: Large multicentre cohort study confirming that several genetic and clinical factors influence the clinical course of CD. NOD2 and early immunomodulator use are the clinically most meaningful predictors.

 

The NOD2insC polymorphism is associated with worse outcome following ilealpouch-anal anastomosis for ulcerative colitis.
Tyler AD, Milgrom R, Stempak JM, Xu W, Brumell JH, Muise AM, Sehgal R, Cohen Z, Koltun W, Shen B, Silverberg MS., Gut. 2013 Oct;62(10):1433-9. doi: 10.1136/gutjnl-2011-301957. Epub 2012 Aug 9.

Comments: NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis.

 

Beyond gene discovery in inflammatory bowel disease: the emerging role ofepigenetics.
Ventham NT, Kennedy NA, Nimmo ER, Satsangi J., Gastroenterology. 2013 Aug;145(2):293-308. doi: 10.1053/j.gastro.2013.05.050.Epub 2013 Jun 8.

Comments: Recent progress in identification of genetic factors and epigenitic mechanisms that could affect development and progression of IBD.

 

Adalimumab induces and maintains mucosal healing in patients with Crohn'sdisease: data from the EXTEND trial.
Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W; EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G., Gastroenterology. 2012 May;142(5):1102-1111.e2. doi:10.1053/j.gastro.2012.01.035. Epub 2012 Feb 8.

 

Induction and maintenance therapy with infliximab for children with moderate tosevere ulcerative colitis.
Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS, Kugathasan S, Cohen S, Markowitz J, Escher JC, Veereman-Wauters G, Crandall W, Baldassano R, Griffiths A; T72 Study Group., Clin Gastroenterol Hepatol. 2012 Apr;10(4):391-9.e1. doi:10.1016/j.cgh.2011.11.026. Epub 2011 Dec 8.

 

Adalimumab induces and maintains clinical remission in patients withmoderate-to-severe ulcerative colitis.
Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB., Gastroenterology. 2012 Feb;142(2):257-65.e1-3. doi: 10.1053/j.gastro.2011.10.032.Epub 2011 Nov 4.

 

Switch to adalimumab in patients with Crohn's disease controlled by maintenanceinfliximab: prospective randomised SWITCH trial.
Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, Claessens C, Humblet E, Vande Casteele N, Gils A, Rutgeerts P., Gut. 2012 Feb;61(2):229-34. doi: 10.1136/gutjnl-2011-300755. Epub 2011 Sep 23.

 

Maintenance of remission among patients with Crohn's disease on antimetabolitetherapy after infliximab therapy is stopped.
Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, PorcherR, Paintaud G, Piver E, Colombel JF, Lemann M; Groupe D'etudes Thérapeutiques DesAffections Inflammatoires Digestives., Gastroenterology. 2012 Jan;142(1):63-70.e5; quiz e31. doi:10.1053/j.gastro.2011.09.034. Epub 2011 Sep 22.

 

Adalimumab induces and maintains mucosal healing in patients with Crohn'sdisease: data from the EXTEND trial.
Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W; EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G., Gastroenterology. 2012 May;142(5):1102-1111.e2. doi:10.1053/j.gastro.2012.01.035. Epub 2012 Feb 8.

 

Induction and maintenance therapy with infliximab for children with moderate tosevere ulcerative colitis.
Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS, Kugathasan S, Cohen S, Markowitz J, Escher JC, Veereman-Wauters G, Crandall W, Baldassano R, Griffiths A; T72 Study Group., Clin Gastroenterol Hepatol. 2012 Apr;10(4):391-9.e1. doi:10.1016/j.cgh.2011.11.026. Epub 2011 Dec 8.

 

Adalimumab induces and maintains clinical remission in patients withmoderate-to-severe ulcerative colitis.
Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB., Gastroenterology. 2012 Feb;142(2):257-65.e1-3. doi: 10.1053/j.gastro.2011.10.032.Epub 2011 Nov 4.

 

Switch to adalimumab in patients with Crohn's disease controlled by maintenanceinfliximab: prospective randomised SWITCH trial.
Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, Claessens C, Humblet E, Vande Casteele N, Gils A, Rutgeerts P., Gut. 2012 Feb;61(2):229-34. doi: 10.1136/gutjnl-2011-300755. Epub 2011 Sep 23.

 

Maintenance of remission among patients with Crohn's disease on antimetabolitetherapy after infliximab therapy is stopped.
Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, DupasJL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, PorcherR, Paintaud G, Piver E, Colombel JF, Lemann M; Groupe D'etudes Thérapeutiques DesAffections Inflammatoires Digestives., Gastroenterology. 2012 Jan;142(1):63-70.e5; quiz e31. doi:10.1053/j.gastro.2011.09.034. Epub 2011 Sep 22.

  

Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.
Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group., Gastroenterology. 2015 May;148(5):1035-1058.e3. doi: 10.1053/j.gastro.2015.03.001. Epub 2015 Mar 4. Review.
 

  

Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease.
Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D'Haens G, Loftus EV Jr, Louis E, Panés J, Schölmerich J, Schreiber S, Vecchi M, Branche J, Bruining D, Fiorino G, Herzog M, Kamm MA, Klein A, Lewin M, Meunier P, Ordas I, Strauch U, et al., Gastroenterology. 2015 Jan;148(1):52-63.e3. doi: 10.1053/j.gastro.2014.09.015. Epub 2014 Sep 21.
Comments: Another illness Index…

  

Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies.
Frolkis AD, Lipton DS, Fiest KM, Negrón ME, Dykeman J, deBruyn J, Jette N, Frolkis T, Rezaie A, Seow CH, Panaccione R, Ghosh S, Kaplan GG., Am J Gastroenterol. 2014 Nov;109(11):1739-48. doi: 10.1038/ajg.2014.297. Epub 2014 Oct 21. Review.
Comments: Surgical risk in CD

 

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomisedstudy.
Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA,Salter-Cid L, Gujrathi S, Aranda R, Luo AY., Gut. 2014 Mar;63(3):442-50. doi: 10.1136/gutjnl-2012-303424. Epub 2013 Mar 5.

Comments: A fully human, monoclonal antibody to interferon-?-inducible protein-10 (IP-10 or CXCL10) was studied to suppress inflammatory cell migration in UC. At (10 mg/kg) IV every other week clinical response rate was not significantly improved, but higher concentrations were associated with increased clinical response (87.5% vs 37.0%).

 

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: resultsfrom the randomised CORE II study.
Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L,Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ., Gut. 2014 Mar;63(3):433-41. doi: 10.1136/gutjnl-2012-304258. Epub 2013 Feb 22.

Comments: Budesonide MMX is a novel oral formulation for once daily use because of extended release to the colon; it was safe and more effective than placebo in active, mild-to-moderate UC.

 

Increased effectiveness of early therapy with anti-tumor necrosis factor-a vs an immunomodulator in children with Crohn's disease.
Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, Baldassano R, Crandall W, Rosh J, Pfefferkorn M, Otley A, Heyman MB, LeLeiko N, Baker S, Guthery SL, Evans J, Ziring D, Kellermayer R, Stephens M, Mack D, Oliva-Hemker M, Patel AS, Kirschner B, Moulton D, Cohen S, Kim S, Liu C, Essers J, Kugathasan S, Hyams JS; PRO-KIIDS Research Group., Gastroenterology. 2014 Feb;146(2):383-91. doi: 10.1053/j.gastro.2013.10.027. Epub2013 Oct 23.

Comments: In children with newly diagnosed severe CD, early monotherapy with anti-TNFa produced better overall outcomes at 1 yr an immunomodulator.

 

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy inperianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, Ponsioen CI, van Dullemen HM, Russel M, van Bodegraven AA, van der Woude CJ., Gut. 2014 Feb;63(2):292-9. doi: 10.1136/gutjnl-2013-304488. Epub 2013 Mar 23.

Comments: Adding ciprofloxacine to adalimumab and ciprofloxacin results in more ealy closure of CD fistulas, but this beneficial effect is not maintained after discontinuation of antibiotic therapy.

 

The role of thiopurines in reducing the need for surgical resection in Crohn'sdisease: a systematic review and meta-analysis.
Chatu S, Subramanian V, Saxena S, Pollok RC., Am J Gastroenterol. 2014 Jan;109(1):23-34; quiz 35. doi: 10.1038/ajg.2013.402.Epub 2013 Dec 10.

Comments: Meta-analysis shows that TP use is associated with a 40% lowered risk of surgical resection in CD, but a large proportion of patients still require resectional surgery.

 

Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn's disease:validation of quantitative index of activity.
Hordonneau C, Buisson A, Scanzi J, Goutorbe F, Pereira B, Borderon C, Da Ines D, Montoriol PF, Garcier JM, Boyer L, Bommelaer G, Petitcolin V., Am J Gastroenterol. 2014 Jan;109(1):89-98. doi: 10.1038/ajg.2013.385. Epub 2013Nov 19.

Comments: DW-MREC is a reliable tool to assess inflammation in colonic (ADC) and ileal (Clermont score) CD and its use in daily practice would avoid gadolinium injection.

 

Early administration of azathioprine vs conventional management of Crohn'sDisease: a randomized controlled trial.
Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M,Dupas JL, Reimund JM, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF; Grouped'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)., Gastroenterology. 2013 Oct;145(4):758-65.e2; quiz e14-5. doi:10.1053/j.gastro.2013.04.048. Epub 2013 Apr 30.

Comments: Small study confirming in agreement with the above mentioned study.

 

Effect of thalidomide on clinical remission in children and adolescents withrefractory Crohn disease: a randomized clinical trial.
Lazzerini M, Martelossi S, Magazzù G, Pellegrino S, Lucanto MC, Barabino A,Calvi A, Arrigo S, Lionetti P, Lorusso M, Mangiantini F, Fontana M, Zuin G, PallaG, Maggiore G, Bramuzzo M, Pellegrin MC, Maschio M, Villanacci V, Manenti S,Decorti G, De Iudicibus S, Paparazzo R, Montico M, Ventura A., JAMA. 2013 Nov 27;310(20):2164-73. doi: 10.1001/jama.2013.280777.

Comments: In children and adolescents with refractory Crohn disease, thalidomide compared with placebo resulted in improved clinical remission at 8 weeks of treatment and longer-term maintenance of remission in an open-label follow-up. These findings require replication to definitively determine clinical utility of this treatment.

 

Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, LukasM, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K,Milch C, Parikh A; GEMINI 2 Study Group., N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.

Comments: Vedolizumab treatment in active Crohn's disease led more often to remission than placebo at week 6; pts with a response who continued to receive vedolizumab were more likely to be in remission at week 52. Adverse events were quite common.

 

Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, VanAssche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J,Parikh A; GEMINI 1 Study Group., N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.

Comments: Idem for Ulcerative colitis.

 

Crohn's disease complicated by strictures: a systematic review.
Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ., Gut. 2013 Jul;62(7):1072-84. doi: 10.1136/gutjnl-2012-304353. Epub 2013 Apr 26.

 

Leukoapheresis in Crohn's disease: the final curtain?
Peyrin-Biroulet L, Danese S., Gut. 2013 Apr;62(4):487-8. doi: 10.1136/gutjnl-2012-302774. Epub 2012 Aug 14.

Comments: Granulocye-monocyte apheresis with currently available systems has not yet proven efficiency in Crohn 's disease

 

Serological markers predict inflammatory bowel disease years before thediagnosis.
van Schaik FD, Oldenburg B, Hart AR, Siersema PD, Lindgren S, Grip O, Teucher B, Kaaks R, Bergmann MM, Boeing H, Carbonnel F, Jantchou P, Boutron-Ruault MC,Tjønneland A, Olsen A, Crowe FL, Peeters PH, van Oijen MG, Bueno-de-Mesquita HB., Gut. 2013 May;62(5):683-8. doi: 10.1136/gutjnl-2012-302717. Epub 2012 Jul 26.

Comments: A panel of serological markers seems to predict later development of CD and UC in a low-risk population

 

Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG., Cochrane Database Syst Rev. 2012 Dec 12;12:CD003459. doi:10.1002/14651858.CD003459.pub3.

 

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan BG, Macdonald JK., Cochrane Database Syst Rev. 2012 Oct 17;10:CD000544. doi:10.1002/14651858.CD000544.pub3.

 

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG, Macdonald JK., Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi:10.1002/14651858.CD000543.pub3.

 

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, HanauerSB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G,Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group., N Engl J Med. 2012 Oct 18;367(16):1519-28. doi: 10.1056/NEJMoa1203572.

 

Ciclosporin versus infliximab in patients with severe ulcerative colitisrefractory to intravenous steroids: a parallel, open-label randomised controlled trial.
Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F,Savoye G, Nachury M, Moreau J, Delchier JC, Cosnes J, Ricart E, Dewit O,Lopez-Sanroman A, Dupas JL, Carbonnel F, Bommelaer G, Coffin B, Roblin X, VanAssche G, Esteve M, Färkkilä M, Gisbert JP, Marteau P, Nahon S, de Vos M,Franchimont D, Mary JY, Colombel JF, Lémann M; Groupe d'Etudes Thérapeutiques desAffections Inflammatoires Digestives., Lancet. 2012 Dec 1;380(9857):1909-15. doi: 10.1016/S0140-6736(12)61084-8. Epub2012 Oct 10.

 

Safety and efficacy of antigen-specific regulatory T-cell therapy for patientswith refractory Crohn's disease.
Desreumaux P, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, Nachury M,Brun V, Bastian H, Belmonte N, Ticchioni M, Duchange A, Morel-Mandrino P, NeveuV, Clerget-Chossat N, Forte M, Colombel JF., Gastroenterology. 2012 Nov;143(5):1207-17.e1-2. doi:10.1053/j.gastro.2012.07.116. Epub 2012 Aug 8.

 

Mucosal healing in inflammatory bowel diseases: a systematic review.
Neurath MF, Travis SP., Gut. 2012 Nov;61(11):1619-35. Epub 2012 Jul 27.

 

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W; StudyA3921063 Investigators., N Engl J Med. 2012 Aug 16;367(7):616-24. doi: 10.1056/NEJMoa1112168.

Comments: Preliminary data showing that Tofacitinib, an oral Janus kinase inhibitor, is suppressing the activity of ulcerative colitis

 

Mucosal healing in inflammatory bowel diseases: a systematic review.
Neurath MF, Travis SP., Gut. 2012 Nov;61(11):1619-35. Epub 2012 Jul 27.

Comments: Review of clinical studies pointing out that mucosal healing is the initial event in the suppression of inflammation of deeper layers of the bowel wall, rather than as a sign of complete healing of gut inflammation. The effects of anti-inflammatory or immunosuppressive drugs on mucosal healing are discussed.

 

Rifaximin-extended intestinal release induces remission in patients withmoderately active Crohn's disease.
Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P; Retic StudyGroup (Rifaximin-Eir Treatment in Crohn's Disease)., Gastroenterology. 2012 Mar;142(3):473-481.e4. doi: 10.1053/j.gastro.2011.11.032. Epub 2011 Dec 6.

 

Validation of the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI or Nivscore): a multicenter prospective study.
Niv Y, Ilani S, Levi Z, Hershkowitz M, Niv E, Fireman Z, O'Donnel S, O'Morain C, Eliakim R, Scapa E, Kalantzis N, Kalantzis C, Apostolopoulos P, Gal E., Endoscopy. 2012 Jan;44(1):21-6. doi: 10.1055/s-0031-1291385. Epub 2011 Nov 28.

 

Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements.
Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, Whittaker S,Griffiths AM, Panaccione R; Canadian Association of Gastroenterology SevereUlcerative Colitis Consensus Group., Am J Gastroenterol. 2012 Feb;107(2):179-94; author reply 195. doi:10.1038/ajg.2011.386. Epub 2011 Nov 22.

 

Practice guidance on the management of acute and chronic gastrointestinalproblems arising as a result of treatment for cancer.
Andreyev HJ, Davidson SE, Gillespie C, Allum WH, Swarbrick E; British Society of Gastroenterology; Association of Colo-Proctology of Great Britain and Ireland;Association of Upper Gastrointestinal Surgeons; Faculty of Clinical OncologySection of the Royal College of Radiologists., Gut. 2012 Feb;61(2):179-92. doi: 10.1136/gutjnl-2011-300563. Epub 2011 Nov 4.

 

Increasing incidence and prevalence of the inflammatory bowel diseases with time,based on systematic review.
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI,Panaccione R, Ghosh S, Barkema HW, Kaplan GG., Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30. doi:10.1053/j.gastro.2011.10.001. Epub 2011 Oct 14.

 

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W; StudyA3921063 Investigators., N Engl J Med. 2012 Aug 16;367(7):616-24. doi: 10.1056/NEJMoa1112168.

Comments: Preliminary data showing that Tofacitinib, an oral Janus kinase inhibitor, is suppressing the activity of ulcerative colitis

 

Mucosal healing in inflammatory bowel diseases: a systematic review.
Neurath MF, Travis SP., Gut. 2012 Nov;61(11):1619-35. Epub 2012 Jul 27.

Comments: Review of clinical studies pointing out that mucosal healing is the initial event in the suppression of inflammation of deeper layers of the bowel wall, rather than as a sign of complete healing of gut inflammation. The effects of anti-inflammatory or immunosuppressive drugs on mucosal healing are discussed.

 

Rifaximin-extended intestinal release induces remission in patients withmoderately active Crohn's disease.
Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P; Retic StudyGroup (Rifaximin-Eir Treatment in Crohn's Disease)., Gastroenterology. 2012 Mar;142(3):473-481.e4. doi: 10.1053/j.gastro.2011.11.032. Epub 2011 Dec 6.

 

Validation of the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI or Nivscore): a multicenter prospective study.
Niv Y, Ilani S, Levi Z, Hershkowitz M, Niv E, Fireman Z, O'Donnel S, O'Morain C, Eliakim R, Scapa E, Kalantzis N, Kalantzis C, Apostolopoulos P, Gal E., Endoscopy. 2012 Jan;44(1):21-6. doi: 10.1055/s-0031-1291385. Epub 2011 Nov 28.

 

Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements.
Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, Whittaker S,Griffiths AM, Panaccione R; Canadian Association of Gastroenterology SevereUlcerative Colitis Consensus Group., Am J Gastroenterol. 2012 Feb;107(2):179-94; author reply 195. doi:10.1038/ajg.2011.386. Epub 2011 Nov 22.

 

Practice guidance on the management of acute and chronic gastrointestinalproblems arising as a result of treatment for cancer.
Andreyev HJ, Davidson SE, Gillespie C, Allum WH, Swarbrick E; British Society of Gastroenterology; Association of Colo-Proctology of Great Britain and Ireland;Association of Upper Gastrointestinal Surgeons; Faculty of Clinical OncologySection of the Royal College of Radiologists., Gut. 2012 Feb;61(2):179-92. doi: 10.1136/gutjnl-2011-300563. Epub 2011 Nov 4.

 

Methotrexate for maintenance of remission in ulcerative colitis.
Wang Y, MacDonald JK, Vandermeer B, Griffiths AM, El-Matary W., Cochrane Database Syst Rev. 2015 Aug 11;8:CD007560. doi: 10.1002/14651858.CD007560.pub3. Review.

 

Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies.
Singh S, Al-Darmaki A, Frolkis AD, Seow CH, Leung Y, Novak KL, Ghosh S, Eksteen B, Panaccione R, Kaplan GG., Gastroenterology. 2015 Oct;149(4):928-37. doi: 10.1053/j.gastro.2015.06.001. Epub 2015 Jun 6. Review.

 

Adalimumab therapy is associated with reduced risk of hospitalization in patientswith ulcerative colitis.
Feagan BG(1), Sandborn WJ(2), Lazar A(3), Thakkar RB(4), Huang B(4), Reilly N(4),Chen N(4), Yang M(4), Skup M(4), Mulani P(4), Chao J(4)., Gastroenterology. 2014 Jan;146(1):110-118.e3. doi: 10.1053/j.gastro.2013.09.032. Epub 2013 Sep 22.

Comments: In moderate to severe UC, the addition of adalimumab to standard of care treatment reduced the number of hospitalizations for any cause.

 

A randomised phase I study of etrolizumab (rhuMAb ß7) in moderate to severeulcerative colitis.
Rutgeerts PJ(1), Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B,Schreiber S, Mansfield JC, Williams M, Tang M, Visich J, Wei X, Keir M, Luca D,Danilenko D, Egen J, O'Byrne S., Gut. 2013 Aug;62(8):1122-30. doi: 10.1136/gutjnl-2011-301769. Epub 2012 Jun 20.

Comments: Etrolizumab (rhuMAb β7, anti-β7, PRO145223), a humanised monoclonal antibody targeting the β7 subunit of the heterodimeric integrins a4β7 and aEβ7, which are implicated in leucocyte migration and retention in ulcerative colitis (UC) is well tolerated in moderate to severe UC (phase I study).

 

Management of active Crohn disease.
Cheifetz AS., JAMA. 2013 May 22;309(20):2150-8. doi: 10.1001/jama.2013.4466.

Comments: Review of management of Crohn's disease

 

An update on the use and investigation of probiotics in health and disease.
Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, Sherman PM, Mayer EA., Gut. 2013 May;62(5):787-96. doi: 10.1136/gutjnl-2012-302504. Epub 2013 Mar 8.

 

Similar risk of depression and anxiety following surgery or hospitalization forCrohn's disease and ulcerative colitis.
Ananthakrishnan AN, Gainer VS, Cai T, Perez RG, Cheng SC, Savova G, Chen P,Szolovits P, Xia Z, De Jager PL, Shaw S, Churchill S, Karlson EW, Kohane I,Perlis RH, Plenge RM, Murphy SN, Liao KP., Am J Gastroenterol. 2013 Apr;108(4):594-601. doi: 10.1038/ajg.2012.471. Epub 2013Jan 22.

Comments: The risk of depression 5 years after surgery was 16% and 11% in CD and UC patients, respectively. Female gender and comorbidity are prognostic factors

 

Development of the Paris definition of early Crohn's disease fordisease-modification trials: results of an international expert opinion process.
Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panés J, DaneseS, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E,Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S, Sandborn WJ., Am J Gastroenterol. 2012 Dec;107(12):1770-6. doi: 10.1038/ajg.2012.117.

 

Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ., Cochrane Database Syst Rev. 2012 Nov 14;11:CD004118. doi:10.1002/14651858.CD004118.pub2.

 

Impact of antibodies to infliximab on clinical outcomes and serum infliximablevels in patients with inflammatory bowel disease (IBD): a meta-analysis.
Nanda KS, Cheifetz AS, Moss AC., Am J Gastroenterol. 2013 Jan;108(1):40-7; quiz 48. doi: 10.1038/ajg.2012.363.Epub 2012 Nov 13.

 

Curcumin for maintenance of remission in ulcerative colitis.
Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC., Cochrane Database Syst Rev. 2012 Oct 17;10:CD008424. doi:10.1002/14651858.CD008424.pub2.

 

Andrographis paniculata extract (HMPL-004) for active ulcerative colitis.
Sandborn WJ, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X, Tang T., Am J Gastroenterol. 2013 Jan;108(1):90-8. doi: 10.1038/ajg.2012.340. Epub 2012Oct 9.

 

Efficacy of hepatitis B vaccination and revaccination and factors impacting onresponse in patients with inflammatory bowel disease.
Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M., Am J Gastroenterol. 2012 Oct;107(10):1460-6. doi: 10.1038/ajg.2012.79.

 

Prevalence of symptoms meeting criteria for irritable bowel syndrome ininflammatory bowel disease: systematic review and meta-analysis.
Halpin SJ, Ford AC., Am J Gastroenterol. 2012 Oct;107(10):1474-82. doi: 10.1038/ajg.2012.260. Epub2012 Aug 28.

 

Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED 2nd., Gastroenterology. 2012 Nov;143(5):1218-26.e1-2. doi:10.1053/j.gastro.2012.08.003. Epub 2012 Aug 11.

 

Cost utility of inflammation-targeted therapy for patients with ulcerativecolitis.
Saini SD, Waljee AK, Higgins PD., Clin Gastroenterol Hepatol. 2012 Oct;10(10):1143-51. doi:10.1016/j.cgh.2012.05.003. Epub 2012 May 18.

 

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severeCrohn's disease: unexpected results of a randomised, double-blindplacebo-controlled trial.
Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD,Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumabin Crohn's Disease Study Group., Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17.

 

Endoscopic improvement of mucosal lesions in patients with moderate to severeileocolonic Crohn's disease following treatment with certolizumab pegol.
Hébuterne X, Lémann M, Bouhnik Y, Dewit O, Dupas JL, Mross M, D'Haens G, Mitchev K, Ernault É, Vermeire S, Brixi-Benmansour H, Moreels TG, Mary JY, Marteau P,Colombel JF., Gut. 2013 Feb;62(2):201-8. doi: 10.1136/gutjnl-2012-302262. Epub 2012 Apr 23.

 

Development of the first disability index for inflammatory bowel disease based onthe international classification of functioning, disability and health.
Peyrin-Biroulet L, Cieza A, Sandborn WJ, Coenen M, Chowers Y, Hibi T, Kostanjsek N, Stucki G, Colombel JF; International Programme to Develop New Indexes forCrohn's Disease (IPNIC) group., Gut. 2012 Feb;61(2):241-7. doi: 10.1136/gutjnl-2011-300049. Epub 2011 Jun 5.

 

Prevalence of symptoms meeting criteria for irritable bowel syndrome ininflammatory bowel disease: systematic review and meta-analysis.
Halpin SJ, Ford AC., Am J Gastroenterol. 2012 Oct;107(10):1474-82. doi: 10.1038/ajg.2012.260. Epub2012 Aug 28.

Comments: Symptoms compatible with IBS were significantly higher in patients with IBD compared with non-IBD controls, even among those felt to be in remission

 

Psychological interventions for parents of children and adolescents with chronic illness.
Eccleston C, Palermo TM, Fisher E, Law E., Cochrane Database Syst Rev. 2012 Aug 15;8:CD009660. doi:10.1002/14651858.CD009660.pub2.

 

5-aminosalicylic acid is not protective against colorectal cancer in inflammatorybowel disease: a meta-analysis of non-referral populations.
Nguyen GC, Gulamhusein A, Bernstein CN., Am J Gastroenterol. 2012 Sep;107(9):1298-304; quiz 1297, 1305. doi:10.1038/ajg.2012.198. Epub 2012 Jul 3.

 

Non surgical therapy for anal fissure.
Nelson RL, Thomas K, Morgan J, Jones A., Cochrane Database Syst Rev. 2012 Feb 15;2:CD003431. doi:10.1002/14651858.CD003431.pub3.

 

Stapled versus handsewn methods for colorectal anastomosis surgery.
Neutzling CB, Lustosa SA, Proenca IM, da Silva EM, Matos D., Cochrane Database Syst Rev. 2012 Feb 15;2:CD003144. doi:10.1002/14651858.CD003144.pub2.

 

Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: asystematic review.
Boonstra K, Beuers U, Ponsioen CY., J Hepatol. 2012 May;56(5):1181-8. doi: 10.1016/j.jhep.2011.10.025. Epub 2012 Jan 13.

 

New therapies for inflammatory bowel disease: from the bench to the bedside.
Danese S., Gut. 2012 Jun;61(6):918-32. doi: 10.1136/gutjnl-2011-300904. Epub 2011 Nov 23.

 

Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, inUlcerative Colitis: systematic review and meta-analysis.
Ford AC, Khan KJ, Achkar JP, Moayyedi P., Am J Gastroenterol. 2012 Feb;107(2):167-76; author reply 177. doi:10.1038/ajg.2011.410. Epub 2011 Nov 22.

 

Efficacy of topical 5-aminosalicylates in preventing relapse of quiescentulcerative colitis: a meta-analysis.
Ford AC, Khan KJ, Sandborn WJ, Hanauer SB, Moayyedi P., Clin Gastroenterol Hepatol. 2012 May;10(5):513-9. doi: 10.1016/j.cgh.2011.10.043.Epub 2011 Nov 12.

 

Development of the first disability index for inflammatory bowel disease based onthe international classification of functioning, disability and health.
Peyrin-Biroulet L, Cieza A, Sandborn WJ, Coenen M, Chowers Y, Hibi T, Kostanjsek N, Stucki G, Colombel JF; International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group., Gut. 2012 Feb;61(2):241-7. doi: 10.1136/gutjnl-2011-300049. Epub 2011 Jun 5.

 

Prevalence of symptoms meeting criteria for irritable bowel syndrome ininflammatory bowel disease: systematic review and meta-analysis.
Halpin SJ, Ford AC., Am J Gastroenterol. 2012 Oct;107(10):1474-82. doi: 10.1038/ajg.2012.260. Epub2012 Aug 28.

Comments: Symptoms compatible with IBS were significantly higher in patients with IBD compared with non-IBD controls, even among those felt to be in remission

 

Psychological interventions for parents of children and adolescents with chronic illness.
Eccleston C, Palermo TM, Fisher E, Law E., Cochrane Database Syst Rev. 2012 Aug 15;8:CD009660. doi:10.1002/14651858.CD009660.pub2.

 

5-aminosalicylic acid is not protective against colorectal cancer in inflammatorybowel disease: a meta-analysis of non-referral populations.
Nguyen GC, Gulamhusein A, Bernstein CN., Am J Gastroenterol. 2012 Sep;107(9):1298-304; quiz 1297, 1305. doi:10.1038/ajg.2012.198. Epub 2012 Jul 3.

 

Non surgical therapy for anal fissure.
Nelson RL, Thomas K, Morgan J, Jones A., Cochrane Database Syst Rev. 2012 Feb 15;2:CD003431. doi:10.1002/14651858.CD003431.pub3.

 

Stapled versus handsewn methods for colorectal anastomosis surgery.
Neutzling CB, Lustosa SA, Proenca IM, da Silva EM, Matos D., Cochrane Database Syst Rev. 2012 Feb 15;2:CD003144. doi:10.1002/14651858.CD003144.pub2.

 

Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: asystematic review.
Boonstra K, Beuers U, Ponsioen CY., J Hepatol. 2012 May;56(5):1181-8. doi: 10.1016/j.jhep.2011.10.025. Epub 2012 Jan 13.

 

New therapies for inflammatory bowel disease: from the bench to the bedside.
Danese S., Gut. 2012 Jun;61(6):918-32. doi: 10.1136/gutjnl-2011-300904. Epub 2011 Nov 23.

 

Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, inUlcerative Colitis: systematic review and meta-analysis.
Ford AC, Khan KJ, Achkar JP, Moayyedi P., Am J Gastroenterol. 2012 Feb;107(2):167-76; author reply 177. doi:10.1038/ajg.2011.410. Epub 2011 Nov 22.

 

Efficacy of topical 5-aminosalicylates in preventing relapse of quiescentulcerative colitis: a meta-analysis.
Ford AC, Khan KJ, Sandborn WJ, Hanauer SB, Moayyedi P., Clin Gastroenterol Hepatol. 2012 May;10(5):513-9. doi: 10.1016/j.cgh.2011.10.043.Epub 2011 Nov 12.

 

Transparent cap colonoscopy versus standard colonoscopy to improve caecalintubation.
Morgan J, Thomas K, Lee-Robichaud H, Nelson RL, Braungart S., Cochrane Database Syst Rev. 2012 Dec 12;12:CD008211. doi:10.1002/14651858.CD008211.pub3.

 

Antibiotics for uncomplicated diverticulitis.
Shabanzadeh DM, Wille-Jørgensen P., Cochrane Database Syst Rev. 2012 Nov 14;11:CD009092. doi:10.1002/14651858.CD009092.pub2.

 

Diagnostic yield of small-bowel capsule endoscopy in patients withiron-deficiency anemia: a systematic review.
Koulaouzidis A, Rondonotti E, Giannakou A, Plevris JN., Gastrointest Endosc. 2012 Nov;76(5):983-92. doi: 10.1016/j.gie.2012.07.035.